Absolutely! BP knows that the potential market for a molecule with apabetalone’s likely properties and demonstrated safety is enormous once it gets over the line. All the hard slog has been done for them - preclinical studies, toxicology, phase 1 studies, phase 2, first go at phase 3. The BETonMACE results were obviously very encouraging for several endpoints. Why not pay a few billion (or hopefully more thsn a few) when to push it over the line might need only a couple more years of clinical trial data - routine stuff for BP. On top of that there would be the other patents, and the bonus of becoming the leader in epigenetics overnight - one of the hottest fields of modern medicine along with gene therapy, gene editing, and immuno-oncology. I will be surprised if there is not competition between 2 or 3 companies. It’s a no-brainer to me, but of course only my opinion.